Innovative Pharmaceutical Biotech Limited, an investment holding company, provides genetic testing services in the People’s Republic of China and Hong Kong.
The last earnings update was 106 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Innovative Pharmaceutical Biotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Innovative Pharmaceutical Biotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Innovative Pharmaceutical Biotech. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Innovative Pharmaceutical Biotech's
is considered below, and whether this is a fair price.
Price based on past earnings
Innovative Pharmaceutical Biotech's earnings available for a low price, and how does
this compare to other companies in the same industry?
Innovative Pharmaceutical Biotech has negative assets, we can't compare the value of its assets to the DE Trade Distributors industry average.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Innovative Pharmaceutical Biotech's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovative Pharmaceutical Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Trade Distributors industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Innovative Pharmaceutical Biotech
expected to grow at an
Unable to compare Innovative Pharmaceutical Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Innovative Pharmaceutical Biotech's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Innovative Pharmaceutical Biotech's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Innovative Pharmaceutical Biotech is high growth as no earnings estimate data is available.
Unable to determine if Innovative Pharmaceutical Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
All data from Innovative Pharmaceutical Biotech Company Filings, last reported 7 months ago, and in
Trailing twelve months (TTM)
annual period rather than quarterly.
DB:FRHN Past Revenue, Cash Flow and Net Income Data
Date (Data in HKD Millions)
Net Income *
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
It is difficult to establish if Innovative Pharmaceutical Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
It is difficult to establish if Innovative Pharmaceutical Biotech has efficiently used its assets last year compared to the DE Trade Distributors industry average (Return on Assets) as it is loss-making.
It is difficult to establish if Innovative Pharmaceutical Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Innovative Pharmaceutical Biotech's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Innovative Pharmaceutical Biotech
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Innovative Pharmaceutical Biotech's finances.
The net worth of a company is the difference between its assets and liabilities.
Innovative Pharmaceutical Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Innovative Pharmaceutical Biotech's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Innovative Pharmaceutical Biotech's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is not covered by short term assets, assets are 0.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Innovative Pharmaceutical Biotech Limited, an investment holding company, provides genetic testing services in the People’s Republic of China and Hong Kong. The company also engages in the trading of beauty equipment and products; distribution of bio-industrial products; and securities investment activities. In addition, it is involved in the research, development, and commercialization of oral insulin products; and engages in the healthcare management business. The company was formerly known as United Gene High-Tech Group Limited and changed its name to Innovative Pharmaceutical Biotech Limited in September 2015. Innovative Pharmaceutical Biotech Limited is headquartered in Sheung Wan, Hong Kong.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.